Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Summary for Patients
space
 arrow  Figures/Tables List
space
 arrow  Related articles in Annals
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Lester, S. J.
space
  arrow  Mendelson, J.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

BRIEF COMMUNICATION

Cardiovascular Effects of 3,4-Methylenedioxymethamphetamine: A Double-Blind, Placebo-Controlled Trial

right arrow Steven J. Lester, MD; Matthew Baggott, BA; Susette Welm, MA; Nelson B. Schiller, MD; Reese T. Jones, MD; Elyse Foster, MD; and John Mendelson, MD

19 December 2000 | Volume 133 Issue 12 | Pages 969-973

Background: The psychoactive stimulant 3,4-methylenedioxymethamphetamine (MDMA), also known as "ecstasy," is widely used in nonmedical settings. Little is known about its cardiovascular effects.

Objective: To evaluate the acute cardiovascular effects of MDMA by using transthoracic two-dimensional and Doppler echocardiography.

Design: Four-session, ascending-dose, double-blind, placebo-controlled trial.

Setting: Urban hospital.

Patients: Eight healthy adults who self-reported MDMA use.

Intervention: Echocardiographic effects of dobutamine (5, 20, and 40 µg/kg of body weight per minute) were measured in a preliminary session. Oral MDMA (0.5 and 1.5 mg/kg of body weight) or placebo was administered 1 hour before echocardiographic measurements in three weekly sessions.

Measurements: Heart rate and blood pressure were measured at regular intervals before and after MDMA administration. Echocardiographic measures of stroke volume, ejection fraction, cardiac output, and meridional wall stress were obtained 1 hour after MDMA administration and during dobutamine infusions.

Results: At a dose of 1.5 mg/kg, MDMA increased mean heart rate (by 28 beats/min), systolic blood pressure (by 25 mm Hg), diastolic blood pressure (by 7 mm Hg), and cardiac output (by 2 L/min). The effects of MDMA were similar to those of dobutamine, 20 and 40 µg/kg per minute. Inotropism, measured by using meridional wall stress corrected for ejection fraction, decreased after administration of dobutamine, 40 µg/kg per minute, but did not change after either dose of MDMA.

Conclusions: Modest oral doses of MDMA increase heart rate, blood pressure, and myocardial oxygen consumption in a magnitude similar to dobutamine, 20 to 40 µg/kg per minute. In contrast to dobutamine, MDMA has no measurable inotropic effects.

Author and Article Information
space

From the Mayo Clinic Scottsdale, Scottsdale, Arizona; and University of California, San Francisco, San Francisco, California.

Acknowledgments: The authors thank the staffs of the Drug Dependence Research Center and the General Clinical Research Center and David Nichols, PhD, for donation of MDMA.

Grant Support: By U.S. Public Health Service grants from the National Institute on Drug Abuse, National Institutes of Health (DA01696, DA00053). Part of the study was carried out in the General Research Clinical Center at the University of California, San Francisco, with support of the Division of Research Resources, National Institutes of Health (RR-00079).

Requests for Single Reprints: John Mendelson, MD, Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco, 401 Parnassus Avenue, San Francisco, CA 94143-0984; e-mail, jemmd{at}itsa.ucsf.edu.

Current Author Addresses: Dr. Lester: Mayo Clinic Scottsdale, Cardiology 3A, 13400 East Shea Boulevard, Scottsdale, AZ 85259.

Mr. Baggott, Ms. Welm, and Drs. Jones and Mendelson: Drug Dependence Research Center, University of California, San Francisco, Box CPR-0984, San Francisco, CA 94143-0984.

Drs. Schiller and Foster: Department of Medicine, John Henry Mills Echocardiography Laboratory, University of California, San Francisco, Box 0214, San Francisco, CA 94143.

Author Contributions: Conception and design: S.J. Lester, M. Baggott, N.B. Schiller, E. Foster, J. Mendelson.

Analysis and interpretation of the data: S.J. Lester, S. Welm, N.B. Schiller, E. Foster, J. Mendelson.

Drafting of the article: S.J. Lester, M. Baggott, E. Foster, J. Mendelson.

Critical revision of the article for important intellectual content: S.J. Lester, N.B. Schiller, E. Foster, J. Mendelson.

Final approval of the article: S.J. Lester, N.B. Schiller, R.T. Jones, E. Foster, J. Mendelson.

Provision of study materials or patients: E. Foster.

Statistical expertise: S.J. Lester, S. Welm.

Obtaining of funding: R.T. Jones, J. Mendelson.

Administrative, technical, or logistic support: N.B. Schiller, E. Foster, J. Mendelson.

Collection and assembly of data: M. Baggott, J. Mendelson.


Related articles in Annals:

Summaries for Patients
Cardiovascular Effects of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Annals 2000 133: S64. [Full Text]  



This article has been cited by other articles:


Home page
CirculationHome page
V. L. Vetter, J. Elia, C. Erickson, S. Berger, N. Blum, K. Uzark, and C. L. Webb
Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Circulation, May 6, 2008; 117(18): 2407 - 2423.
[Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. E. Rusyniak, M. V. Zaretskaia, D. V. Zaretsky, and J. A. DiMicco
3,4-Methylenedioxymethamphetamine- and 8-Hydroxy-2-di-n-propylamino-tetralin-Induced Hypothermia: Role and Location of 5-Hydroxytryptamine 1A Receptors
J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 477 - 487.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
G. J. H. Dumont and R. J. Verkes
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
J Psychopharmacol, March 1, 2006; 20(2): 176 - 187.
[Abstract] [PDF]


Home page
Journal Watch CardiologyHome page
Unique Cardiovascular Danger Associated with 'Ecstasy'
Journal Watch Cardiology, March 2, 2001; 2001(302): 7 - 7.
[Full Text]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2000 by the American College of Physicians.